134 related articles for article (PubMed ID: 15630436)
1. A new mechanism of BRAF activation in human thyroid papillary carcinomas.
Fusco A; Viglietto G; Santoro M
J Clin Invest; 2005 Jan; 115(1):20-3. PubMed ID: 15630436
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Ciampi R; Knauf JA; Kerler R; Gandhi M; Zhu Z; Nikiforova MN; Rabes HM; Fagin JA; Nikiforov YE
J Clin Invest; 2005 Jan; 115(1):94-101. PubMed ID: 15630448
[TBL] [Abstract][Full Text] [Related]
3. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
4. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
5. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
Lee JH; Lee ES; Kim YS; Won NH; Chae YS
Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
[TBL] [Abstract][Full Text] [Related]
7. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
8. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
9. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
10. Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutations in papillary carcinomas of the thyroid.
Fukushima T; Suzuki S; Mashiko M; Ohtake T; Endo Y; Takebayashi Y; Sekikawa K; Hagiwara K; Takenoshita S
Oncogene; 2003 Sep; 22(41):6455-7. PubMed ID: 14508525
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.
Moretti S; Macchiarulo A; De Falco V; Avenia N; Barbi F; Carta C; Cavaliere A; Melillo RM; Passeri L; Santeusanio F; Tartaglia M; Santoro M; Puxeddu E
Oncogene; 2006 Jul; 25(30):4235-40. PubMed ID: 16501605
[TBL] [Abstract][Full Text] [Related]
15. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
16. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of BRAF mutation in thyroid carcinoma.
Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
[TBL] [Abstract][Full Text] [Related]
19. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
20. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]